This article identifies 13 innovative stocks recommended by Wall Street analysts. It highlights Veracyte, Inc. (NASDAQ: VCYT) as an example, detailing UBS’s reaffirmed Buy rating, a $48 price target, and positive commentary on its Q4 testing revenue, 2026 projections, and adjusted EBITDA margin. The company is a genomic diagnostics firm specializing in cancer and autoimmune disease tests.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
This article identifies 13 innovative stocks recommended by Wall Street analysts. It highlights Veracyte, Inc. (NASDAQ: VCYT) as an example, detailing UBS’s reaffirmed Buy rating, a $48 price target, and positive commentary on its Q4 testing revenue, 2026 projections, and adjusted EBITDA margin. The company is a genomic diagnostics firm specializing in cancer and autoimmune disease tests.